

5<sup>th</sup> March 2025

The Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, 5th floor,  
Bandra-Kurla Complex  
Bandra (E)  
Mumbai – 400051  
Symbol: AKZOINDIA

Dear Sir / Madam,

**Sub: Clarification for Financial results - AKZOINDIA**

We refer to your mail dated 3<sup>rd</sup> March 2025 on the subject.

In this regard, we would like to inform you that though both Standalone and Consolidated Financial Statements optically looks similar, however, have differences in the following line-items:

- a. 'Employee benefit expense' amounting to Rs. 773 Million in Standalone Financial Statement vis-à-vis Rs. 776 Million in Consolidated Financial Statement; and
- b. 'Other expenses' amounting to Rs. 1,960 Million in Standalone Financial Statement vis-à-vis Rs. 1,957 Million in Consolidated Financial Statement.

Further, since the subsidiary's income is solely from its parent (i.e. Akzo Nobel India) by way of providing services, the net financial impact is nil in the Consolidated Financial Statement, thereby leading to it optically looking same.

Hope this clarifies the matter.

Thanking you,

Yours truly,  
for **Akzo Nobel India Limited**

Rajiv L Jha  
Company Secretary & Compliance Officer  
Membership No. F5948